Cargando…

Challenges for Relative Effectiveness Assessment and Early Access of Cancer Immunotherapies in Europe

Clinical endpoints relevant for relative effectiveness assessment (REA) reflect how patients feel, function, or survive. Outcome data requested by health technology assessment (HTA) bodies in Europe to support reimbursement of an anticancer drug are based on final endpoints coming from completed com...

Descripción completa

Detalles Bibliográficos
Autor principal:	Pavlovic, Mira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107821/ https://www.ncbi.nlm.nih.gov/pubmed/27896268 http://dx.doi.org/10.3389/fmed.2016.00056

Ejemplares similares

Core Values of Family Medicine in Europe: Current State and Challenges
por: Arvidsson, Eva, et al.
Publicado: (2021)

Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges
por: Iyer, Rohin K., et al.
Publicado: (2018)

Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe
por: Sepodes, Bruno, et al.
Publicado: (2021)

Challenges of Providing Access to Cutting-Edge Cancer Medicines in the Countries of Eastern Europe
por: Tomić, Zdenko, et al.
Publicado: (2018)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Cell Tracking in Cancer Immunotherapy
por: Perrin, Justine, et al.
Publicado: (2020)

Role of a Pyroptosis-Related lncRNA Signature in Risk Stratification and Immunotherapy of Ovarian Cancer
por: Zhang, Zeyu, et al.
Publicado: (2022)

Challenges in the equitable access to COVID-19 vaccines for migrant populations in Europe
por: Armocida, Benedetta, et al.
Publicado: (2021)

MAGE-A Antigens and Cancer Immunotherapy
por: Zajac, Paul, et al.
Publicado: (2017)

Characteristics of dust mite sublingual immunotherapy-associated adverse events in the early phase
por: Chen, Ming, et al.
Publicado: (2022)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy
por: Zaiachuk, Mariia, et al.
Publicado: (2021)

Supporting Primary Care Professionals to Stay in Work During the COVID-19 Pandemic: Views on Personal Risk and Access to Testing During the First Wave of Pandemic in Europe
por: Wanat, Marta, et al.
Publicado: (2021)

Commentary: Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
por: Kuhbandner, Christof, et al.
Publicado: (2020)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Challenges and Opportunities for Effective Cancer Immunotherapies
por: Slaney, Clare Y., et al.
Publicado: (2020)

Malaria in Europe: A Historical Perspective
por: Boualam, Mahmoud A., et al.
Publicado: (2021)

Editorial: Global excellence in gastroenterology: Europe
por: Abenavoli, Ludovico
Publicado: (2023)

Editorial: Global excellence in rheumatology: Europe
por: Alunno, Alessia, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
por: Chick, Robert Connor, et al.
Publicado: (2023)

Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda
por: Vassal, Gilles, et al.
Publicado: (2014)

Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?
por: Spaas, Mathieu, et al.
Publicado: (2019)

COVID-19–Related Fatalities and Intensive-Care-Unit Admissions by Age Groups in Europe: A Meta-Analysis
por: Cohen, Jérémie F., et al.
Publicado: (2021)

Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe
por: Akhmetov, Ildar, et al.
Publicado: (2015)

Bibliographic access in Europe : first international conference
Publicado: (1990)

Case Report: Post-mortem Histopathological and Molecular Analyses of the Very First Documented COVID-19-Related Death in Europe
por: Bogdanović, Milenko, et al.
Publicado: (2021)

Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
por: Canales Albendea, Miguel Á., et al.
Publicado: (2023)

Hurdles and delays in access to anti-cancer drugs in Europe
por: Ades, F, et al.
Publicado: (2014)

Health Care Accessibility and Breast Cancer Mortality in Europe
por: Ciuba, Agata, et al.
Publicado: (2022)

Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma
por: Li, Zhouhua, et al.
Publicado: (2022)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Active Ageing in Europe: Adding Healthy Life to Years
por: Liotta, Giuseppe, et al.
Publicado: (2018)

Paediatric Medicines in Europe: The Paediatric Regulation—Is It Time for Reform?
por: Toma, Maddalena, et al.
Publicado: (2021)

Editorial: Hot Topics in Pancreatology From Europe-2020
por: Capurso, Gabriele, et al.
Publicado: (2021)

Barriers to Treg therapy in Europe: From production to regulation
por: Hennessy, Conor, et al.
Publicado: (2023)

Editorial: Global excellence in gene and cell therapy: Europe
por: Mendonça, Liliana, et al.
Publicado: (2023)

When to initiate early palliative care? Challenges faced by healthcare providers
por: Vitorino, Joel Vieira, et al.
Publicado: (2023)

Vaccine Immunotherapy for Celiac Disease
por: Di Sabatino, Antonio, et al.
Publicado: (2018)

Immunotherapy for Pemphigus: Present and Future
por: Yuan, Huijie, et al.
Publicado: (2022)

Early Detection and Assessment of Covid-19
por: Hashmi, Hafiz Abdul Sattar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1djoqpr0i3dkeq1q0m2i2rrcvc